Novartis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Lichtstrasse 35, Basel, Basel-City, 4056...Phone Number
+41613241111Website
www.novartis.comRevenue
$56.7 BillionStock Symbol
NVSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
3
4
2
1
1
About Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novartis maintains a significant presence in scientific research, with extensive operations spanning across Europe, North America, Asia, and other global regions.Explore more
Novartis Org Chart
TN
Head of Financial Reporting Accounting, Novar...
FM
Group Planning, Reporting & Digital Finance H...
SA
Supervisor, General Ledger & Product Cost Con...
WT
Controller
WH
KPI Controller
VV
Lacan Refs Financial Controller
HS
Financial Controller
VP
Credit Controller
TS
Financial Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novartis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Novartis is spiking on competitors!
Click to see if Novartis had a recent Job posting/layoffs
Novartis, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Novartis has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Novartis launches new products
Website visits: Recent activity has been detected on your website
Check if Novartis has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Novartis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Novartis
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Explore company insights
Get a deeper look into Novartis's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Novartis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novartis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novartis.
Novartis Tech Stack
A closer look at the technologies used by Novartis
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Novartis News & Media
'Discovery, mentorship, momentum': UC College of Medicine's graduate programs celebrate ...
From new mentorship honors to a growing research pipeline, see how the University of Cincinnati College of Medicine's graduate programs made this a standout year.Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving 251 patients with early-stage ALS. The drug targeted TREM2, a protein involved in immune responses and inflammation in the brain. Novartis will stop […]Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1. It marked the company’s third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen […]Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novartis
Sign Up For FreeTo access detailed company insights
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novarti... Read More
